ACAA2の乳化と発現は,フェニルフリン誘発の心筋細胞増殖におけるミトコンドリア機能障害を媒介する
Yingying Guo1, Meng Zhang2, Wanyi Li1
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, 430060, PR China.
Biochemical and biophysical research communications
|August 26, 2025
まとめ
アチル-CoA受容体タンパク質2 (ACAA2) のダウンレギュレーションおよびその乳化により,ミトコンドリアの機能が低下することで,心臓の大幅化が悪化する. ACAA2の復元は 心不全の治療策となるかもしれません
科学分野:
- 心血管生物学
- 代謝の調節
- エピジェネティクス
背景:
- 心臓の病理的な改造には 代謝の再プログラムが含まれており 乳糖化が重要な調節因子として現れる.
- 乳酸は乳化媒介による表遺伝的変化によって細胞過程に影響する.
- 脂肪酸酸化酵素であるACAA2は,心臓エネルギーにおけるその役割について調査されています.
研究 の 目的:
- ACAA2の乳化ダイナミクスを調査する.
- 圧力過負荷による心筋病変における ACAA2 の代謝的影響を調査する.
- ACAA2の機能的役割を病理性心筋縮で決定する.
主な方法:
- 横動脈収縮 (TAC) のマウスと偽のコントロールにおけるRNAシーケンシング.
- ネズミの新生児の心室筋細胞 (NRVMs) のフェニルエフリン (PE) 刺激により,縮を誘発する.
- ACAA2の乳化が免疫降水とRNA干渉による機能分析によって確認される.
- ELISAとシーホースXF分析器を用いた基板利用とミトコンドリア呼吸の評価
主要な成果:
- ACAA2は拡張性心筋病患者およびTACマウスでダウン調節され,心臓機能と相関していました.
- ACAA2のノックダウンにより,PE誘発の縮が悪化し,全体的な乳化が低下した.
- ACAA2の静止は脂肪酸の蓄積を増加させ,乳酸とATPを減少させ,ミトコンドリアの呼吸を阻害し,乳酸によって部分的に救出されました.
結論:
- ACAA2発現と乳化の変化は,病理的な心筋縮に寄与する.
- ミトコンドリアの酸化リン酸化機能障害は,ACAA2媒介による効果に関与しています.
- ACAA2は,心不全の予防と治療のための潜在的な治療目標です.
関連する概念動画
Heart Failure II: Pathophysiology
38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38
Cardiomyopathy III: Hypertrophic Cardiomyopathy
47
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
47
Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
ATP Synthase: Mechanism
15.1K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
15.1K
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K


